CN107496402A - A kind of sulforaphane with resisiting influenza virus effect and its preparation method and application - Google Patents

A kind of sulforaphane with resisiting influenza virus effect and its preparation method and application Download PDF

Info

Publication number
CN107496402A
CN107496402A CN201710736749.6A CN201710736749A CN107496402A CN 107496402 A CN107496402 A CN 107496402A CN 201710736749 A CN201710736749 A CN 201710736749A CN 107496402 A CN107496402 A CN 107496402A
Authority
CN
China
Prior art keywords
sulforaphane
buffer solution
influenza
influenza virus
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710736749.6A
Other languages
Chinese (zh)
Other versions
CN107496402B (en
Inventor
李占省
刘玉梅
方智远
杨丽梅
庄木
张扬勇
吕红豪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing shuxingyuan Technology Co.,Ltd.
Original Assignee
Institute of Vegetables and Flowers Chinese Academy of Agricultural Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Vegetables and Flowers Chinese Academy of Agricultural Sciences filed Critical Institute of Vegetables and Flowers Chinese Academy of Agricultural Sciences
Priority to CN201710736749.6A priority Critical patent/CN107496402B/en
Publication of CN107496402A publication Critical patent/CN107496402A/en
Application granted granted Critical
Publication of CN107496402B publication Critical patent/CN107496402B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/18—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms
    • C07C331/20—Isothiocyanates having isothiocyanate groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds

Abstract

The invention provides a kind of new application of sulforaphane as anti-influenza virus medicament, sulforaphane has the activity of good resisiting influenza virus in low strength range, and without significant cytotoxicity, the quantity of influenza virus infected cell can be improved, there is the potential value as Tamiflu active ingredient.

Description

A kind of sulforaphane with resisiting influenza virus effect and its preparation method and application
Technical field
The invention belongs to broccoli extract field, is related to a kind of sulforaphane and its system with resisiting influenza virus effect Preparation Method and application.
Background technology
Influenza, abbreviation influenza, it is a kind of Acute respiratory infectious disease as caused by influenza virus, is common in Child, and have the baby, children and the elderly of underlying diseases often prognosis is bad.Influenza virus is a kind of RNA virus, and category is just glutinous Liquid Viraceae, a variety of hosts such as people, birds and pig can be infected, cause acute upper respiratory infection, even life is threatened when serious Life.The World Health Organization (WHO) estimation, the annual about 1,000,000,000 people's influenza virus infections in the whole world, wherein there are about 500,000 people therefore It is dead.
Four types of influenza virus point：A type (Influenza A virus), B-mode (Influenza B virus), third Type (Influenza C virus) and fourth type (Influenza D virus), wherein A type and influenza B virus are to cause people The most important reason of class disease and seasonal epidemics.According to viral major structural protein hemagglutinin HA and neuraminidase NA Antigenicity, influenza A virus is divided into 16 H hypotypes (H1-H16) and 9 N hypotypes (N1-N9).2009, Flu-A disease The great outburst of the malicious H1N1 whole world, individual countries and regions more than 200 are spread to, nearly 20,000 people of death toll, serious warp are caused to the whole world Ji loss, this let us clear-headed infectiousness and harmfulness of recognizing that influenza virus is huge.
At present, prevention and treatment influenza mainly uses vaccine.However, influenza virus has extremely strong antigenic mutation, epidemic disease The effect of seedling is unstable, meanwhile, vaccine only has prevention effect to known influenza virus, invalid to novel influenza.Cause This, a kind of safe and effective compound with resisiting influenza virus effect of exploitation, has great importance.
Sulforaphane (sulforaphane, SF) is the isothiocyanic acid salt material that a kind of molecular weight is 177.29, mainly By the precursor substance 4- methanesulfinyl butyl sulphur glucosides (glucoraphanin, GRA or RAA) being present in broccoli, through enzymolysis Reaction generation.Research finds that sulforaphane can significantly reduce stomach cancer, liver cancer, lung cancer, breast cancer, colon cancer and carcinoma of urinary bladder etc. The incidence of disease of cancer, in addition, also there is significant work(in treatment myopia, senile dementia, cardiovascular and cerebrovascular disease, hypertension etc. Effect.
The A of CN 104427981 are disclosed comprising sulforaphane or sulforaphane precursor and the group of mushroom extract or powder Compound, said composition have the function that treatment, prevention breast cancer；The A of CN 104968342 are disclosed for treating or reducing liver The sulforaphane of insulin resistance, have the function that to improve hepatic insulin susceptibility；The B of CN 101167741 disclose radish The anti-cancer combination preparation of sulfane and platinum class medicine, it is mainly used in the treatment of non-small cell lung cancer, ED-SCLC；CN 107007578 A discloses sulforaphane and is preparing the application in treating leukemia medicament, and sulforaphane, which has, promotes apoptosis of leukemia to enter And suppress the ability of Leukemia Cell Proliferation.However, the technology for being used to prevent and treat influenza there is presently no sulforaphane opens Show.
The content of the invention
In view of the above-mentioned problems, the present invention provide a kind of sulforaphane and preparation method thereof with resisiting influenza virus effect and Using sulforaphane has the potential value as anti-influenza virus medicament.
In a first aspect, the invention provides a kind of new application of sulforaphane as anti-influenza virus medicament.
The sulforaphane of the present invention has the activity of good resisiting influenza virus in low strength range, and without significant thin Cellular toxicity, the quantity for the cell that influenza virus is infected can be improved, there is the potential value as Tamiflu active ingredient.
According to the present invention, the invention provides a kind of application of sulforaphane as the medicine for preparing treatment influenza virus.
Preferably, the concentration of the sulforaphane is 5.0-30.0 μM, for example, can be 5.0 μM, 6.0 μM, 6.25 μM, 8.0 μM, 10.0 μM, 12.0 μM, 12.5 μM, 15.0 μM, 18.0 μM, 20.0 μM, 22.0 μM, 25.0 μM, 28.0 μM or 30.0 μM, Preferably 6.0-25.0 μM, more preferably 6.25-12.5 μM.
Preferably, the influenza virus includes influenza A virus and/or influenza B virus, preferably Flu-A disease Poison.
Preferably, the medicine also includes pharmaceutically acceptable carrier.
Preferably, the preparation method of the sulforaphane comprises the following steps：
(1) digest：Buffer solution is added into sample, carries out enzyme digestion reaction；
(2) extract：Extractant is added, supernatant is collected by centrifugation, obtains the sulforaphane.
Preferably, any one in the seed of step (1) described sample including Vegetables in Brassica, flower, stem or leaf or extremely Few two kinds combination, preferably broccoli seeds.
Preferably, step (1) described buffer solution includes KH2PO4-K2HPO4Buffer solution, Na2HPO4- citrate buffer solution, lemon In lemon acid-sodium citrate buffer solution or acetate buffer solution any one or at least two combination, preferably KH2PO4- K2HPO4Buffer solution.
Preferably, the concentration of step (1) described buffer solution is 0.05-0.2M, for example, can be 0.05M, 0.06M, 0.07M、0.08M、0.09M、0.10M、0.11M、0.12M、0.13M、0.14M、0.15M、0.16M、0.17M、0.18M、0.19M Or 0.20M, preferably 0.1M.
Preferably, the pH value of step (1) described buffer solution is 6.0-8.0, for example, can be 6.0,6.1,6.2,6.3, 6.4th, 6.5,6.6,6.7,6.8,6.9,7.0,7.1,7.2,7.3,7.4,7.5,7.6,7.7,7.8,7.9 or 8.0, be preferably 7.0。
Preferably, the solid-liquid ratio of step (1) sample and the buffer solution is 1:(20-50), such as can be 1:20、 1:22、1:25、1:28、1:30、1:32、1:35、1:38、1:40、1:42、1:45、1:48 or 1:50, preferably 1:30.
Preferably, the temperature of step (1) described enzyme digestion reaction is 15-35 DEG C, for example, can be 15 DEG C, 16 DEG C, 17 DEG C, 18 ℃、19℃、20℃、21℃、22℃、23℃、24℃、25℃、26℃、27℃、28℃、29℃、30℃、31℃、32℃、33 DEG C, 34 DEG C or 35 DEG C, preferably 25 DEG C.
Preferably, the time of step (1) described enzyme digestion reaction is 1.0-2.0h, for example, can be 1.0h, 1.1h, 1.2h, 1.3h, 1.4h, 1.5h, 1.6h, 1.7h, 1.8h, 1.9h or 2.0h, preferably 1.5h.
Preferably, step (2) described extractant include ethyl acetate, petroleum ether, benzene or chloroform in any one or extremely Few two kinds combination, preferably ethyl acetate.
Preferably, the speed of step (2) described centrifugation is 4000-6000rpm, for example, can be 4000rpm, 4200rpm, 4500rpm, 4800rpm, 5000rpm, 5200rpm, 5500rpm, 5800rpm or 6000rpm, preferably 5500rpm.
Preferably, the time of step (2) described centrifugation is 5-20min, for example, can be 5min, 6min, 7min, 8min, 9min, 10min, 11min, 12min, 13min, 14min, 15min, 16min, 17min, 18min, 19min or 20min, preferably For 10min.
Preferably, also including being evaporated the step of constant volume filters after step (2).
Preferably, described the step of being evaporated constant volume filtering, specifically includes：Supernatant is evaporated, entered after constant volume using filter membrane Row filtering.
Preferably, the temperature being evaporated is 30-40 DEG C, for example, can be 30 DEG C, 31 DEG C, 32 DEG C, 33 DEG C, 34 DEG C, 35 DEG C, 36 DEG C, 37 DEG C, 38 DEG C, preferably 39 DEG C or 40 DEG C, 35 DEG C.
Preferably, the solvent of the constant volume includes any one in dimethyl sulfoxide (DMSO), deionized water, ethanol or ethyl oleate Kind or at least two combination, preferably dimethyl sulfoxide (DMSO).
Preferably, the aperture of the filter membrane is 0.2-0.4 μm, for example, can be 0.2 μm, 0.21 μm, 0.22 μm, 0.23 μm、0.24μm、0.25μm、0.26μm、0.27μm、0.28μm、0.29μm、0.30μm、0.31μm、0.32μm、0.33μm、0.34 μm, 0.35 μm, 0.36 μm, 0.37 μm, 0.38 μm, preferably 0.39 μm or 0.40 μm, 0.22 μm.
As optimal technical scheme, the preparation method of the sulforaphane comprises the following steps：
(1) digest：It is the KH that 0.05-0.2M, pH are 6.0-8.0 that concentration is added into sample2PO4-K2HPO4Buffer solution, 1.0-2.0h is stirred at 15-35 DEG C and carries out enzyme digestion reaction, wherein, the sample and the KH2PO4-K2HPO4The feed liquid of buffer solution Than for 1:(20-50)；
(2) add extractant to be extracted, 5-20min is centrifuged under 4000-6000rpm, collect supernatant, repeat 2-3 times；
(3) supernatant that step (2) obtains is rotated at 30-40 DEG C and be evaporated, added 10.0mL solvents and carry out constant volume, make After 0.22 μm of filtering membrane filtration, saved backup at -20 DEG C.
Compared with prior art, the present invention has the advantages that：
(1) sulforaphane of the invention has most strong anti influenza in the low strength range that concentration is 6.25-12.5 μM The activity of virus, and without significant cytotoxicity；
(2) sulforaphane that concentration is 6.25 μM is added in the mdck cell infected to influenza virus, can be improved 19.2% cell number；
(3) sulforaphane is extracted from broccoli seeds using the method for the present invention, content is up to 5512.63mg/L FW, purity is preferable, and detection peak is not disturbed by impurity.
Brief description of the drawings
Fig. 1 (A) is the chromatogram of sulforaphane standard items and sulforaphane extract, and Fig. 1 (B) is sulforaphane in 5.0- Linear relationship chart in the range of 300.0mg/L；
Fig. 2 is the fluorescent value after the sulforaphane standard items and sulforaphane extract-treated mdck cell of various concentrations；
Fig. 3 is that the sulforaphane standard items of various concentrations handle the microphoto after mdck cell.
Embodiment
For the technological means and its effect that the present invention is taken is expanded on further, with reference to embodiments with accompanying drawing to this hair It is bright to be further described.It is understood that embodiment described herein is used only for explaining the present invention, rather than Limitation of the invention.
In the examples where no specific technique or condition is specified, according to the technology or condition described by document in the art, Or carried out according to product description.Agents useful for same or the unreceipted production firm person of instrument, be can be by regular channel commercially available from The conventional products of acquisition.
The preparation of the sulforaphane of embodiment 1 (I)
(1) digest：It is the KH that 0.1M, pH are 7.0 that concentration is added into broccoli seeds2PO4-K2HPO4Buffer solution, 25 DEG C Lower stirring 1.5h carries out enzyme digestion reaction, wherein, the broccoli seeds and the KH2PO4-K2HPO4The solid-liquid ratio of buffer solution is 1:30；
(2) add ethyl acetate to be extracted, 10min is centrifuged under 5500rpm, collect supernatant, repeat 2-3 times；
(3) supernatant that step (2) obtains is rotated at 35 DEG C and be evaporated, added 10.0mL dimethyl sulfoxide (DMSO)s and determined Hold, after 0.22 μm of filtering membrane filtration, saved backup at -20 DEG C.
The preparation of the sulforaphane of embodiment 2 (II)
(1) digest：It is the Na that 0.15M, pH are 7.5 that concentration is added into blue and white cauliflower2HPO4- citrate buffer solution, 30 DEG C Lower stirring 1.2h carries out enzyme digestion reaction, wherein, the blue and white cauliflower and the Na2HPO4The solid-liquid ratio of-citrate buffer solution is 1: 40；
(2) add petroleum ether to be extracted, 15min is centrifuged under 5000rpm, collect supernatant, repeat 2-3 times；
(3) supernatant that step (2) obtains is rotated at 32 DEG C and is evaporated, added 10.0mL deionized waters and carry out constant volume, After 0.3 μm of filtering membrane filtration, saved backup at -20 DEG C.
The preparation of the sulforaphane of embodiment 3 (III)
(1) digest：It is citric acid-sodium citrate buffer solution that 0.05M, pH are 6.0 that concentration is added into broccoli stem, 35 1.0h is stirred at DEG C and carries out enzyme digestion reaction, wherein, the broccoli stem and the solid-liquid ratio of the citric acid-sodium citrate buffer solution For 1:20；
(2) add benzene to be extracted, 20min is centrifuged under 4000rpm, collect supernatant, repeat 2-3 times；
(3) supernatant that step (2) obtains is rotated at 30 DEG C and be evaporated, added 10.0mL ethanol and carry out constant volume, use After 0.4 μm of filtering membrane filtration, saved backup at -20 DEG C.
The preparation of the sulforaphane of embodiment 4 (IV)
(1) digest：It is the acetate buffer solution that 0.2M, pH are 8.0 that concentration is added into blue and white dish leaf, and 2.0h is stirred at 15 DEG C Enzyme digestion reaction is carried out, wherein, the solid-liquid ratio of the blue and white dish leaf and the acetate buffer solution is 1:50；
(2) add chloroform to be extracted, 5min is centrifuged under 6000rpm, collect supernatant, repeat 2-3 times；
(3) supernatant that step (2) obtains is rotated at 40 DEG C and is evaporated, added 10.0mL ethyl oleates and carry out constant volume, After 0.2 μm of filtering membrane filtration, saved backup at -20 DEG C.
The detection of sulforaphane and content analysis
The detection of sulforaphane is using the SHIMADZU LC-20A chromatographs equipped with SPD-20 UV-detectors, chromatogram Post uses the anti-phase C18 posts (250 × 4.6mm, 5 μm) of SHISEIDO companies, and the flow velocity of mobile phase is 0.800mLmin-1, inspection Survey wavelength is 254nm, and the temperature of chromatographic column is 32 DEG C；Elution program uses gradient method, wherein, the eluent of A pumps is the four of 5% The hydrogen furans aqueous solution, initial concentration are set as that the eluent of 60%, B pumps is hplc grade methanol, and initial concentration is set as 40%, After 10min, the concentration of B pumps is changed into after 60%, A pumps are changed into 40%, 25min, and B pumps are changed into 100%, now terminate sample introduction, sample introduction Measure as 10 μ L.
The content of sulforaphane prepared by embodiment 1-4 is as shown in table 1.
Numbering The content (mg/L FW) of sulforaphane
Embodiment 1 5512.63
Embodiment 2 5429.67
Embodiment 3 5298.46
Embodiment 4 5049.31
Wherein, the content highest of sulforaphane prepared by embodiment 1, is 5512.63mg/L FW.From Fig. 1 (A), system Do not disturbed by impurity at the detection peak of standby obtained sulforaphane；From Fig. 1 (B), sulforaphane is in 5.0-300.0mg/L scopes Interior to have well linear, linear equation is：
Y=2.76 × 10-4x-0.73(R2=0.9998)
The cytopathic effect of embodiment 5 determines
Mdck cell is inoculated in 96 porocyte plates, is added influenza virus (MOI=0.1) and is infected overnight.
Respectively the mdck cell (C+V) to influenza infection and not in by the mdck cell (C) of influenza infection plus Enter the sulforaphane extract that concentration is 6.25,12.5,25.0,50.0 and 100.0 μM, after hatching 40h, add fluorescence activity thing Matter, carried out using Tecan Infinite M2000 PROTM (Tecan Group Ltd., Mannedorf, Switzerland) Fluorescence reading, while use the observation of microscope progress cytoactive.
Embodiment 6
It is 1000mgL by concentration-1Sulforaphane standard mother liquor (U.S. LKTTM, purity >=98%) diluted with DMSO Into the standard items that series concentration is 6.25,12.5,25.0,50.0 and 100.0 μM.Compared with Example 5, embodiment 6 adds dense The sulforaphane standard items for 6.25,12.5,25.0,50.0 and 100.0 μM are spent, other conditions are same as Example 5.
Comparative example 1
Compared with Example 5, comparative example 1 adds medicine Tamiflu (OSV), and other conditions are same as Example 5.
Comparative example 2
Compared with Example 5, comparative example 2 adds the DMSO that concentration is 0.5%, and other conditions are same as Example 5.
As a result as shown in table 2, Fig. 2 and Fig. 3.In table 2 and Fig. 2, C represents the cell not infected by influenza virus, and C+V is represented The cell infected by influenza virus, capitalization represent there is significant difference in 0.01 level；In Fig. 3, transparent cell It is show that dead cell quantity is much more.
Influence of the 2 different samples of table to mdck cell fluorescence intensity
As a result show, the mdck cell that the sulforaphane infected by influenza of various concentrations infects has different degrees of resistance Reaction, concentration are that 6.25-12.5 μM of sulforaphane has the activity of most strong resisiting influenza virus.
From figures 2 and 3, it will be seen that the sulforaphane standard items of embodiment 6 shown in the range of 6.25-25.0 μM it is good The activity of good resisiting influenza virus, and do not have significant cytotoxicity, and the sulforaphane extract of embodiment 5 is in concentration The activity of good resisiting influenza virus is shown at 6.25-12.5 μM.
Compared with comparative example 2, in embodiment 5, concentration be 6.25 μM of sulforaphane extract improve 18% it is thin Born of the same parents' number, in embodiment 6,19.2% He has been respectively increased for the sulforaphane standard items of 6.25 μM and 12.5 μM concentration in concentration 17.8% cell number, and the positive drug Tamiflu (OSV) of comparative example 1 improves 40.0% cell number, shows sulforaphane Activity with resisiting influenza virus.
The sulforaphane extract and standard items of remaining concentration also show the activity of certain resisiting influenza virus, but together When also show certain cytotoxicity.
In summary, sulforaphane of the invention has well in the low strength range that concentration is 6.25-12.5 μM The activity of resisiting influenza virus, and without significant cytotoxicity；Sulforaphane is added in the mdck cell infected to influenza virus, can To improve cell proliferation number；Sulforaphane is extracted from broccoli seeds using the method for the present invention, purity is preferable, and detection peak is not Disturbed by impurity.
Applicant states that the present invention illustrates the method detailed of the present invention, but not office of the invention by above-described embodiment It is limited to above-mentioned method detailed, that is, does not mean that the present invention has to rely on above-mentioned method detailed and could implemented.Art Technical staff it will be clearly understood that any improvement in the present invention, equivalence replacement and auxiliary element to each raw material of product of the present invention Addition, selection of concrete mode etc., within the scope of all falling within protection scope of the present invention and disclosing.

Claims (10)

  1. A kind of 1. new application of sulforaphane as anti-influenza virus medicament.
  2. 2. purposes according to claim 1, it is characterised in that the concentration of the sulforaphane is 5.0-30.0 μM, preferably For 6.0-25.0 μM, more preferably 6.25-12.5 μM.
  3. 3. purposes according to claim 1 or 2, it is characterised in that the influenza virus include influenza A virus and/or Influenza B virus, preferably influenza A virus.
  4. 4. according to the purposes described in claim any one of 1-3, it is characterised in that the medicine also includes pharmaceutically acceptable Carrier.
  5. 5. according to the purposes described in claim any one of 1-4, it is characterised in that the preparation method of the sulforaphane is included such as Lower step：
    (1) digest：Buffer solution is added into sample, carries out enzyme digestion reaction；
    (2) extract：Extractant is added, supernatant is collected by centrifugation, obtains the sulforaphane.
  6. 6. purposes according to claim 5, it is characterised in that seed of step (1) the described sample including Vegetables in Brassica, In flower, stem or leaf any one or at least two combination, preferably broccoli seeds.
  7. 7. the purposes according to claim 5 or 6, it is characterised in that step (1) described buffer solution includes KH2PO4-K2HPO4 Buffer solution, Na2HPO4In-citrate buffer solution, citric acid-sodium citrate buffer solution or acetate buffer solution any one or extremely Few two kinds combination, preferably KH2PO4-K2HPO4Buffer solution；
    Preferably, the concentration of step (1) described buffer solution is 0.05-0.2M, preferably 0.1M；
    Preferably, the pH value of step (1) described buffer solution is 6.0-8.0, preferably 7.0；
    Preferably, the solid-liquid ratio of step (1) sample and the buffer solution is 1:(20-50), preferably 1:30；
    Preferably, the temperature of step (1) described enzyme digestion reaction is 15-35 DEG C, preferably 25 DEG C；
    Preferably, the time of step (1) described enzyme digestion reaction is 1.0-2.0h, preferably 1.5h.
  8. 8. according to the purposes described in claim any one of 5-7, it is characterised in that step (2) described extractant includes acetic acid second In ester, petroleum ether, benzene or chloroform any one or at least two combination, preferably ethyl acetate；
    Preferably, the speed of step (2) described centrifugation is 4000-6000rpm, preferably 5500rpm；
    Preferably, the time of step (2) described centrifugation is 5-20min, preferably 10min.
  9. 9. according to the purposes described in claim any one of 5-8, it is characterised in that also include being evaporated constant volume after step (2) The step of filtering；
    Preferably, described the step of being evaporated constant volume filtering, specifically includes：Supernatant is evaporated, carried out after constant volume using filter membrane Filter；
    Preferably, the temperature being evaporated is 30-40 DEG C, preferably 35 DEG C；
    Preferably, the solvent of the constant volume include dimethyl sulfoxide (DMSO), deionized water, ethanol or ethyl oleate in any one or At least two combination, preferably dimethyl sulfoxide (DMSO)；
    Preferably, the aperture of the filter membrane is 0.2-0.4 μm, preferably 0.22 μm.
  10. 10. according to the purposes described in claim any one of 5-9, it is characterised in that the preparation method of the sulforaphane includes Following steps：
    (1) digest：It is the KH that 0.05-0.2M, pH are 6.0-8.0 that concentration is added into sample2PO4-K2HPO4Buffer solution, 15-35 1.0-2.0h is stirred at DEG C and carries out enzyme digestion reaction, wherein, the sample and the KH2PO4-K2HPO4The solid-liquid ratio of buffer solution is 1:(20-50)；
    (2) add extractant to be extracted, 5-20min is centrifuged under 4000-6000rpm, collect supernatant, repeat 2-3 times；
    (3) supernatant that step (2) obtains is rotated at 30-40 DEG C and be evaporated, added 10.0mL solvents and carry out constant volume, use After 0.22 μm of filtering membrane filtration, saved backup at -20 DEG C.
CN201710736749.6A 2017-08-24 2017-08-24 Sulforaphane with anti-influenza virus effect and preparation method and application thereof Active CN107496402B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710736749.6A CN107496402B (en) 2017-08-24 2017-08-24 Sulforaphane with anti-influenza virus effect and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710736749.6A CN107496402B (en) 2017-08-24 2017-08-24 Sulforaphane with anti-influenza virus effect and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN107496402A true CN107496402A (en) 2017-12-22
CN107496402B CN107496402B (en) 2020-10-16

Family

ID=60692894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710736749.6A Active CN107496402B (en) 2017-08-24 2017-08-24 Sulforaphane with anti-influenza virus effect and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN107496402B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1982294A (en) * 2005-12-13 2007-06-20 北京化工大学 Preparation of raphanin sulfane
WO2009111486A2 (en) * 2008-03-04 2009-09-11 The Regents Of The University Of California Reversing the immune decline of aging by a nutraceutical antioxidant in mice

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1982294A (en) * 2005-12-13 2007-06-20 北京化工大学 Preparation of raphanin sulfane
WO2009111486A2 (en) * 2008-03-04 2009-09-11 The Regents Of The University Of California Reversing the immune decline of aging by a nutraceutical antioxidant in mice

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MATTHEW J.KESIC，等: ""Nrf2 expression modifies influenza A entry and replication in nasal epithelial cells"", 《FREE RADICAL BIOLOGY & MEDICINE》 *
MEGAN MEYER，等: ""Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants"", 《AM J PHYSIOL LUNG CELL MOL PHYSIOL》 *
任德权: "《制药工程科技与教育展望》", 30 November 2005, 华东理工大学出版社 *
李占省，等: ""青花菜 DH 群体花球中莱菔硫烷含量的遗传效应分析"", 《园艺学报》 *
牛广财等: "《果蔬加工学》", 31 August 2010, 中国计量出版社 *

Also Published As

Publication number Publication date
CN107496402B (en) 2020-10-16

Similar Documents

Publication Publication Date Title
Ullah et al. Bioactivity profile of the diterpene isosteviol and its derivatives
US20110142966A1 (en) Aqueous extracts of anoectochilus spp. kinsenoside and pharmaceutical compositions useful for hepatoprotection
Huang et al. Hepatoprotective principles and other chemical constituents from the mycelium of Phellinus linteus
Nie et al. Phytochemistry and pharmacological activities of the diterpenoids from the genus Daphne
Sánchez-Ramos et al. Establishment of a cell suspension culture of Ageratina pichinchensis (Kunth) for the improved production of anti-inflammatory compounds
CN101240005A (en) Method for preparing platycodin D from balloon-flower root and application thereof in anti-cancer medicament
Ribeiro et al. Determination of the catechin contents of bioactive plant extracts using disposable screen-printed carbon electrodes in a batch injection analysis (BIA) system
Teng et al. Recent progresses in marine microbial-derived antiviral natural products
CN101824067A (en) Barrigenol-type triterpenoid saponins compound, preparation method and application thereof
CN108003214A (en) A kind of saponin compound and its methods and applications extracted from the rhizoma bolbostemmae
Gonring-Salarini et al. In vitro antiplasmodial activities of alkaloids isolated from roots of Worsleya procera (Lem.) Traub (Amaryllidaceae)
Mottaghipisheh Oxypeucedanin: Chemotaxonomy, isolation, and bioactivities
CN103627772B (en) The preparation method of a kind of triptolide alcohol derivative and product thereof and application
Mahendran et al. Sodium nitroprusside enhances biomass and gymnemic acids production in cell suspension of Gymnema sylvestre (Retz.) R. Br. ex. Sm.
CN104873570B (en) A kind of method for extraction and purification of Prunella vulgaris general flavone and its application
Malarz et al. Constituents of Pulicaria inuloides and cytotoxic activities of two Methoxylated Flavonols
CN107496402A (en) A kind of sulforaphane with resisiting influenza virus effect and its preparation method and application
CN115260022B (en) Macrocyclic diphenyl heptane, preparation method and application thereof in preparation of anti-influenza virus drugs
Antúnez-Mojica et al. Lignans from bursera fagaroides: Chemistry, pharmacological effects and molecular mechanism. A current review
Aminkar et al. Quantitative assessment of diosgenin from different ecotypes of Iranian fenugreek (Trigonella foenum-graecum L.) by high-performance liquid chromatography.
Sun et al. Stachydrine, a Bioactive Equilibrist for Synephrine, Identified from Four Citrus Chinese Herbs
Sun et al. Karrikins-induced accumulation of salvianolic acid B is regulated by jasmonic acid and hydrogen peroxide in Salvia miltiorrhiza
CN100584837C (en) Hydroxy stilbene kind compound and its preparation method and application
Othman et al. Acylphenols and dimeric acylphenols from the genus Myristica: a review of their phytochemistry and pharmacology
Jafernik et al. Schisandra henryi—A rare species with high medicinal potential

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220214

Address after: 102200 Room 302, floor 3, building 7, yard 18, Jingxing street, Changping District, Beijing

Patentee after: Beijing shuxingyuan Technology Co.,Ltd.

Address before: 100081 No. 12 South Main Street, Haidian District, Beijing, Zhongguancun

Patentee before: THE INSTITUTE OF VEGETABLES AND FLOWERS CHINESE ACADEMY OF AGRICULTURAL SCIENCES

TR01 Transfer of patent right